SLC5A2 and lupus nephritis: Those treated with SGLT2 inhibitors had significant reduced risk for lupus nephritis [adjusted hazard ratio (AHR) 0.55; 95% CI: 0.40–0.77], dialysis (AHR 029; 95% CI: 0.17–0.48), kidney transplant (AHR 0.14, 95% CI: 0.03–0.62), heart failure (AHR 0.65, 95% CI: 0.53–0.78) and all-cause mortality (AHR 0.35, 95% CI: 0.26–0.47) (84).